
51 - 200 employees
𧬠Biotechnology
π Pharmaceuticals
π° $96.9M Post-IPO Equity - Rezolute on 2025-04
Biotechnology β’ Pharmaceuticals
Rezolute, Inc. is a biopharmaceutical company focused on developing and delivering novel therapies for rare metabolic disorders, specifically hyperinsulinism. The companyβs lead program, ersodetug, has two Phase 3 programs targeting congenital and tumor hyperinsulinism, and Rezolute conducts clinical trials, investigator-initiated studies, and publishes clinical outcomes. Rezolute also engages with patients, investors, and the medical community to improve care and quality of life for affected patients and families.
π₯ 7 minutes ago
Senior Medical Science Liaison managing medical relationships in metabolic and oncologic space for Rezolute. Engaging with global thought leaders and supporting medical information delivery.
πΊπΈ United States β Remote
π΅ $170k - $220k / year
π° $96.9M Post-IPO Equity - Rezolute on 2025-04
β° Full Time
π Senior